Diagenode and Alithea Genomics collaborate to offer scalable and affordable RNA-seq services
Diagenode expands services offering by introducing new high-throughput 3'mRNA sequencing service that utilizes MERCURIUS technology
DENVILLE, N.J. and LIEGE, Belgium, July 30, 2020 /PRNewswire-PRWeb/ -- Diagenode, a leading global provider of solutions for epigenetics research and sample preparation, has partnered with Alithea Genomics to provide a novel low cost, high performance 3' mRNA-seq service to help advance transcriptomics research.
The new Alithea-powered technology, known as "MERCURIUS", enables reliable gene expression quantification across the transcriptome with accurate differential analysis. The technology is highly scalable for large investigational studies, allowing the assessment of multiple conditions of interest or increasing statistical power underlying differential expression analysis with larger sets of replicates. The innovative barcoding approach supporting the new service makes the analysis of large cohorts of samples robust and cost efficient.
Diagenode brings deep expertise to commercializing this service for RNA researchers to help them to gain insight into processes such as cellular differentiation, carcinogenesis, transcription regulation and biomarker discovery among others. In addition to the company's long history in developing advanced technologies for epigenomics services across DNA, RNA, and chromatin, Diagenode recently launched a unique D-Plex small RNA-seq library preparation solution for low inputs and high diversity as well as a bioinformatics data mining services - which addresses the challenge of analyzing RNA-seq data by applying machine learning, statistics, and database systems.
"The new Diagenode high-throughput 3'mRNA-seq service provides an excellent solution to identify genes that are differentially expressed in distinct cell populations, or in response to different treatments," said Caroline Quoilin, Product Manager at Diagenode. "This service allows for the processing of a large number of samples simultaneously and will help researchers to investigate cell development mechanisms, to determine the molecular dysregulation that causes cancer and other diseases, and to study drug mode of action."
Caroline Quoilin expanded, "We are committed to expanding our services to make RNA research optimal and accessible for labs of any size and budget."
"We strongly believe that the combination of Diagenode's outreach and Alithea's technology will translate into a successful partnership," said Riccardo Dainese, CEO of Alithea Genomics. "This partnership will enable us to reliably and efficiently provide the benefits of the MERCURIUS technology on a large scale, for the benefits of its final users, who will finally have at their disposal a high-quality yet cost-efficient RNA sequencing solution."
To learn more about Diagenode's services, please visit: https://www.diagenode.com/en/p/high-throughput-3mrna-seq-services
About Alithea Genomics S.A:
Alithea Genomics is a young Swiss startup that recently spun off of the Swiss Institute of Technology (EPFL) in Lausanne. Alithea develops solutions of high-throughput bulk transcriptomics based on its proprietary technology called MERCURIUS. For more information about Alithea Genomics, please visit the company's website at http://www.alitheagenomics.com.
About Diagenode:
Diagenode is a leading provider of complete solutions for epigenetic research and epigenomics services. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, non coding RNA-seq, ChIP, and ChIP-seq workflows. The company's latest innovations include a unique, full automation system, a Reduced Representation Bisulfite Sequencing (RRBS) Kit providing eight times more coverage than standard technologies, ChIPmentation and ChIP-seq kits for only 10,000 cells, and the industry's most validated antibodies. For more information about Diagenode, please visit the company's website at http://www.diagenode.com.
SOURCE Diagenode Inc
Share this article